Aug 13, 2026 04:42PM
Aug 13, 2026 04:42PM
Aug 11, 2026 05:02PM
Aug 11, 2026 04:01PM
May 12, 2026 05:19PM
May 12, 2026 04:01PM
Apr 22, 2026 05:14AM Maze Therapeutics prices $150 million stock offering at $23.50 per share
Apr 22, 2026 12:09AM
Mar 25, 2026 07:47AM
Mar 25, 2026 07:00AM
Mar 25, 2026 07:00AM
Mar 25, 2026 07:00AM
Nov 6, 2025 04:01PM
Nov 6, 2025 07:01AM Maze Therapeutics presents drug data at kidney conference
Nov 6, 2025 07:00AM
Oct 6, 2025 07:01AM
Oct 6, 2025 07:00AM
Sep 11, 2025 07:35AM
Sep 11, 2025 07:35AM
Sep 11, 2025 07:30AM
Sep 11, 2025 07:30AM Maze Therapeutics Announces Positive First-in-Human Results from Phase 1 Trial of MZE782, Establishing Proof of Mechanism for a Potent, Oral SLC6A19 Inhibitor with Potential to Treat Phenylketonuria (
Sep 2, 2025 07:00AM
Sep 2, 2025 07:00AM
Aug 12, 2025 04:55PM
Aug 12, 2025 04:01PM
May 15, 2025 05:23PM
May 14, 2025 04:01PM
Mar 31, 2025 07:30AM Maze Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Highlights
Feb 7, 2025 08:01AM
Feb 7, 2025 08:00AM

1,219,080 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All